Insights & Resources

Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Weaver professionals discuss the U.S. Supreme Court’s decision to overturn the Chevron doctrine, cybersecurity and accounting reminders on goodwill impairment.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.

Cybersecurity is critically important, especially for school districts. For educators, an understanding of cybersecurity’s best practices cannot be overstated.

The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.

As cloud-based solutions streamline business processes, cloud outages can greatly disrupt organizations and leave financial and reputational impacts.

High-growth specialties are influencing the fair market value of ambulatory surgery centers and setting new standards for premium valuations.